AU2005215874B2 - Anti-EpCAM immunoglobulins - Google Patents

Anti-EpCAM immunoglobulins Download PDF

Info

Publication number
AU2005215874B2
AU2005215874B2 AU2005215874A AU2005215874A AU2005215874B2 AU 2005215874 B2 AU2005215874 B2 AU 2005215874B2 AU 2005215874 A AU2005215874 A AU 2005215874A AU 2005215874 A AU2005215874 A AU 2005215874A AU 2005215874 B2 AU2005215874 B2 AU 2005215874B2
Authority
AU
Australia
Prior art keywords
cancer
immunoglobulin
epcam
administration
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005215874A
Other languages
English (en)
Other versions
AU2005215874A1 (en
Inventor
Mathias Locher
Malte Peters
Nadja Prang
Cornelia Quadt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Research Munich GmbH
Original Assignee
Amgen Research Munich GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Research Munich GmbH filed Critical Amgen Research Munich GmbH
Publication of AU2005215874A1 publication Critical patent/AU2005215874A1/en
Application granted granted Critical
Publication of AU2005215874B2 publication Critical patent/AU2005215874B2/en
Assigned to AMGEN RESEARCH (MUNICH) GMBH reassignment AMGEN RESEARCH (MUNICH) GMBH Request to Amend Deed and Register Assignors: MICROMET AG
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2005215874A 2004-02-13 2005-02-09 Anti-EpCAM immunoglobulins Ceased AU2005215874B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/778,915 US20050180979A1 (en) 2004-02-13 2004-02-13 Anti-EpCAM immunoglobulins
US10/778,915 2004-02-13
PCT/EP2005/001307 WO2005080428A2 (en) 2004-02-13 2005-02-09 Anti-epcam immunoglobulins

Publications (2)

Publication Number Publication Date
AU2005215874A1 AU2005215874A1 (en) 2005-09-01
AU2005215874B2 true AU2005215874B2 (en) 2011-01-27

Family

ID=34838270

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005215874A Ceased AU2005215874B2 (en) 2004-02-13 2005-02-09 Anti-EpCAM immunoglobulins

Country Status (23)

Country Link
US (3) US20050180979A1 (enExample)
EP (2) EP1713830B1 (enExample)
JP (1) JP5220315B2 (enExample)
KR (1) KR101236224B1 (enExample)
CN (1) CN1976951B (enExample)
AT (1) ATE437186T1 (enExample)
AU (1) AU2005215874B2 (enExample)
BR (1) BRPI0507660A (enExample)
CA (1) CA2555694C (enExample)
DE (1) DE602005015544D1 (enExample)
DK (1) DK1713830T3 (enExample)
EA (1) EA011951B1 (enExample)
ES (1) ES2328159T3 (enExample)
IL (1) IL177069A (enExample)
MX (1) MXPA06008942A (enExample)
NO (1) NO339364B1 (enExample)
NZ (1) NZ549125A (enExample)
PL (1) PL1713830T3 (enExample)
PT (1) PT1713830E (enExample)
SI (1) SI1713830T1 (enExample)
UA (1) UA87128C2 (enExample)
WO (1) WO2005080428A2 (enExample)
ZA (1) ZA200606083B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070122406A1 (en) 2005-07-08 2007-05-31 Xencor, Inc. Optimized proteins that target Ep-CAM
EP2474822A1 (en) 2003-01-24 2012-07-11 University of Utah Methods of predicting mortality risk by determining telomere length
AU2007213920B2 (en) * 2006-02-09 2013-08-29 Amgen Research (Munich) Gmbh Treatment of metastatic breast cancer
DK2041181T3 (da) * 2006-06-08 2011-08-29 Helmholtz Zentrum Muenchen Specifikke proteaseinhibitorer og deres anvendelse i cancerterapi
EP1865001A1 (en) * 2006-06-08 2007-12-12 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Specific protease inhibitors and their use in cancer therapy
EP2142570B1 (en) * 2007-04-04 2011-06-15 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Anti-epcam antibody and uses thereof
CA2748265C (en) 2008-12-22 2018-04-03 University Of Utah Research Foundation Monochrome multiplex quantitative pcr
EP2480687B1 (en) * 2009-09-21 2015-01-28 Paul Walfish Methods and compositions for the diagnosis and treatment of thyroid cancer
EP2819695B1 (en) * 2012-03-02 2018-06-27 Academia Sinica ANTI-EPITHELIAL CELL ADHESION MOLECULE (EpCAM) ANTIBODIES AND METHODS OF USE THEREOF
CN103387988B (zh) * 2012-09-24 2016-01-06 厦门大学 上皮细胞粘附分子的核酸适体EpCAM Ccut及其制备方法
EP2999800B1 (en) 2013-05-22 2019-09-25 Telomere Diagnostics Inc. Measures of short telomere abundance
CN103275226B (zh) * 2013-06-09 2017-08-29 中国科学技术大学 特异性抗人上皮细胞粘附分子（EpCAM）的单克隆抗体的制备、鉴定及应用
ES2728668T3 (es) * 2014-01-08 2019-10-28 Univ Leland Stanford Junior Terapia dirigida para el cáncer de pulmón de células pequeñas
CA2971169A1 (en) 2014-12-30 2016-07-07 Telomere Diagnostics, Inc. Multiplex quantitative pcr
AU2016358296B2 (en) * 2015-11-19 2020-05-21 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
KR20190038567A (ko) 2016-07-26 2019-04-08 테사 테라퓨틱스 피티이. 엘티디. 키메라 항원 수용체
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046645A2 (en) * 1997-04-14 1998-10-22 Micromet Gesellschaft Für Biomedizinische Forschung Mbh Method for the production of antihuman antigen receptors and uses thereof
US20030092160A1 (en) * 1999-04-15 2003-05-15 Abraham Bout Recombinant protein production in a human cell

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5853697A (en) * 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
DK1383785T3 (da) * 2001-05-03 2011-05-23 Merck Patent Gmbh Rekombinant tumorspecifikt antistof og anvendelse deraf
US20030175268A1 (en) * 2002-01-11 2003-09-18 Saint-Remy Jean-Marie R. Method and pharmaceutical composition for preventing and/or treating systemic inflammatory response syndrome
PL375064A1 (en) * 2002-05-20 2005-11-14 Abgenix, Inc. Treatment of renal carcinoma using antibodies against the egfr

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046645A2 (en) * 1997-04-14 1998-10-22 Micromet Gesellschaft Für Biomedizinische Forschung Mbh Method for the production of antihuman antigen receptors and uses thereof
US20030092160A1 (en) * 1999-04-15 2003-05-15 Abraham Bout Recombinant protein production in a human cell

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Lewis et al. Current Opinion in Molecular Therapeutics 2003, 5(4), 433-436 *

Also Published As

Publication number Publication date
WO2005080428A2 (en) 2005-09-01
PL1713830T3 (pl) 2010-01-29
JP2008500277A (ja) 2008-01-10
JP5220315B2 (ja) 2013-06-26
DK1713830T3 (da) 2009-10-12
PT1713830E (pt) 2009-10-19
CN1976951B (zh) 2012-03-14
US20120294873A1 (en) 2012-11-22
ATE437186T1 (de) 2009-08-15
HK1096103A1 (en) 2007-05-25
ZA200606083B (en) 2007-10-31
WO2005080428A3 (en) 2005-11-10
SI1713830T1 (sl) 2009-10-31
EA200601386A1 (ru) 2007-06-29
NO20064136L (no) 2006-11-07
MXPA06008942A (es) 2007-01-26
AU2005215874A1 (en) 2005-09-01
US20050180979A1 (en) 2005-08-18
KR20070009988A (ko) 2007-01-19
IL177069A0 (en) 2006-12-10
US20070274982A1 (en) 2007-11-29
CA2555694A1 (en) 2005-09-01
KR101236224B1 (ko) 2013-02-22
BRPI0507660A (pt) 2007-07-17
UA87128C2 (ru) 2009-06-25
EA011951B1 (ru) 2009-06-30
NZ549125A (en) 2008-09-26
NO339364B1 (no) 2016-12-05
EP2107071A2 (en) 2009-10-07
CA2555694C (en) 2013-04-16
EP1713830A2 (en) 2006-10-25
EP1713830B1 (en) 2009-07-22
EP2107071A3 (en) 2009-12-30
DE602005015544D1 (de) 2009-09-03
CN1976951A (zh) 2007-06-06
ES2328159T3 (es) 2009-11-10
IL177069A (en) 2010-11-30

Similar Documents

Publication Publication Date Title
US20120294873A1 (en) ANTI-EpCAM IMMUNOGLOBULINS
EP3505535B1 (en) Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof
CN106967172B (zh) 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
WO2020043184A1 (zh) 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
CN101365486B (zh) 使用抗egfr和抗her2抗体的联合治疗
US20110274688A1 (en) Prevention of tumors with monoclonal antibodies against neu
WO1994022478A1 (en) PREVENTION OF TUMORS WITH MONOCLONAL ANTIBODIES AGAINST $i(NEU)
CN114044827B (zh) 低adcc/cdc功能性单抗及其制备方法与应用
KR20230093282A (ko) 폐암에 대한 lag-3 길항제 요법
CN121108344A (zh) 抗cd3抗体以及其用途
JP2023554422A (ja) がんの治療のための多重特異性抗体
CN112672759B (zh) 抗程序性死亡配体-1(pd-l1)抗体的抗肿瘤用途
HK1096103B (en) Anti-epcam immunoglobulins
WO2023227115A1 (en) A method of treating solid tumor
WO2025088496A1 (en) Combination of antibody-drug conjugate and anti-pd-1/tim-3 bispecific binding protein
TW202432585A (zh) 癌症新輔助治療的組合物及方法
KR20240038204A (ko) Pd-1에 특이적으로 결합하는 항체를 유효성분으로 포함하는 신경내분비 신생물의 예방 또는 치료용 약학 조성물
Garrett Peptide-based B-cell epitope vaccines targeting HER-2/neu
WO2023198839A2 (en) Bispecific antibodies against cd3 and cd20
CN120529917A (zh) 使用抗CTLA4抗体与Pembrolizumab组合治疗癌症的方法
HK40010330B (en) Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PATENTEE TO READ AMGEN RESEARCH (MUNICH) GMBH .

MK14 Patent ceased section 143(a) (annual fees not paid) or expired